The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
about
Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccinationRandomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerEfficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.VIN usual type-from the past to the futureCross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic VaccinesVLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusA pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2Capsomer vaccines protect mice from vaginal challenge with human papillomavirusRationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.Safety of human papillomavirus vaccines: a review.Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implicationsImpact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.Modeling optimal cervical cancer prevention strategies in Nigeria.Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types.Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodiesEfficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Cost-effectiveness of different human papillomavirus vaccines in SingaporeComprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian WomenLow avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalenceHuman papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPVMulti-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England.HPV in HIV-Infected Women: Implications for Primary PreventionVaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.Prevalence and molecular epidemiology of human papillomavirus infection in italian women with cervical cytological abnormalities.Integrating clinical, community, and policy perspectives on human papillomavirus vaccinationIn vivo mechanisms of vaccine-induced protection against HPV infection.Asian society of gynecologic oncology workshop 2010Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervixEfficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies
P2860
Q21261267-AF7C100E-AA87-4DCC-BC5D-C3664F0951E9Q24600011-5A40E184-9FD7-4939-8B18-32C88F785C5DQ24607403-7E8B5113-60A3-49F2-8500-1BE9905307BFQ24614644-B400E80B-4AA2-4836-8368-E14564BA67DAQ26765429-B37BB2E3-C5C1-42F3-A157-E69CB996D2F1Q26828840-1D3C85E0-F96B-4AD0-81C0-08E8DCCEE157Q26865303-C390867A-3EEF-40BA-A0A0-234C005E57A4Q28085724-513AA64A-0415-498F-B9CC-55880C4BBFD6Q28280059-7A1849F5-999E-49DF-9F61-35F195935549Q28741364-8FAF0E46-D5CA-4AF7-9131-FD36C2F5B2E2Q28743261-271C1A74-5154-4451-A1F1-09708C57F284Q30300329-EBAAC346-6E3A-4592-8F35-6A72EF2D2950Q30573204-105A5C96-E9EC-425F-ABA2-3CB08B9A22C0Q30667372-9BD9F7A0-2795-4C61-B554-2E0273B01277Q33162724-98FD255F-EA9C-4774-9390-B54288F2938EQ33469751-F1F6659A-9128-4B65-B965-5586290C89E0Q33591582-D4220334-E1C1-42C4-ADED-652B63B60776Q33708098-8428FAEE-D210-4F46-9CE7-174C12C6B87CQ33724422-BD0A9861-91D3-4CA1-8706-88557A1ED40EQ33755002-AB888DB8-9D29-4E7D-ACB3-B25BAEA39BC9Q33774640-31053301-6F02-4831-9427-B2F2DE0D8C7EQ33780651-B604F6D8-7A24-48C4-B0AE-13C74EA8C941Q33791312-1F1E9A75-1558-44D8-9B7D-D09F560855C3Q33810515-028600A3-0363-49C3-879A-F3A6BE001AB3Q33856453-6E8D64E2-6427-4266-9463-C6402D358241Q33859018-86D98E28-504A-4080-8C2A-B5296737E9EBQ33859491-99B4F425-A5E9-41EF-9354-A984E0220E58Q33924580-511A13C4-1C68-4A70-ADE1-780AC76D6478Q33963857-2274FF6A-FC69-49F5-8470-A70B0AD97054Q34005902-D95433E2-F79A-406D-9E06-3EB26F40FA83Q34033445-9F3CC7BE-6E15-4D6C-8C14-9561627E3766Q34054427-3767DDCE-B994-41D9-8FD4-A20CD04E6195Q34074208-14153887-78CD-434A-9895-B9E179E66F9AQ34078572-36AE83A0-718F-49EE-A90D-FE5283435B01Q34125906-A21FEC37-9D35-4548-9F18-9BB0706032EEQ34167035-E880663F-CB45-4788-854E-BEB879C622BFQ34181909-17F510B1-BA36-48FB-BCD4-845C315EDAE9Q34187128-D9F64603-643A-4080-BDB0-0B0605D84ED8Q34199560-B83C1AB4-5236-4FC6-B321-9E4786C9788BQ34199773-0CE7C6C5-D8BE-41EC-AEC2-E34B96ACFD28
P2860
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
The impact of quadrivalent hum ...... -naive women aged 16-26 years.
@en
type
label
The impact of quadrivalent hum ...... -naive women aged 16-26 years.
@en
prefLabel
The impact of quadrivalent hum ...... -naive women aged 16-26 years.
@en
P2093
P50
P356
P1476
The impact of quadrivalent hum ...... -naive women aged 16-26 years.
@en
P2093
Amha Tadesse
Daron G Ferris
Darron R Brown
Eliav Barr
Elmar A Joura
Eng Hseon Tay
Evan R Myers
F Xavier Bosch
Frank J Taddeo
Gonzalo Perez
P304
P356
10.1086/597307
P407
P577
2009-04-01T00:00:00Z